Pharmaceuticals maker Merck & Co., Inc. (
) on Friday received some bullish commentary from analysts at
The firm maintained its "Buy" rating and $45 price target on
MRK, suggesting just a 5% upside to the stock's Thursday closing
price of $42.91. UBS noted that the company's new osteoporosis
drug, dubbed Odanacatib, has shown promise in recently trials.
Merck shares, which have risen nearly 14% year-to-date, were
mostly flat in premarket trading Friday.
The Bottom Line
Shares of Merck (
) have a 3.92% dividend yield, based on last night's closing stock
price of $42.91. The stock has technical support in the $38-$39
price area. If the shares can firm up, we see overhead resistance
around the $45-$47 price levels.
Merck & Co., Inc. (
) is not recommended at this time, holding a Dividend.com DARS™
Rating of 3.4 out of 5 stars.
Be sure to visit our complete recommended list of the
Best Dividend Stocks
, as well as a detailed explanation of
our ratings system here
Created by Dividend.com